The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting on new developments on the other hand.
Who will benefit from this newsletter?
Any professionals interested in keeping up with developments around multiple myeloma:
There were a total of 30K mentions from patients recorded during the listening period from June 1st, 2023, to June 30th, 2023.
A majority of mentions came from News (46%), Twitter (42%), Tumblr (7%), Forums (2%), Reddit (1%), Blogs (1%) and Instagram (1%).
*: Myeloma OR multiplemyeloma OR #Mmsm OR #Myeloma* OR #Curemyeloma* OR #Mmmrd OR #mmsm OR title: ("multiple myeloma" OR myeloma)
This year’s edition was heavily focused on CAR-T cell therapies and bispecific antibodies.
Highly anticipated results from the CARTITUDE-4 reflect this. Other development of note include teclistamab and talquetamab and corresponding trials RedirecTT-1 and MajesTEC-1.
Overall bispecific antibodies elranatamab and talquetamab took center stage online during #eha23 with the results of MagnetisMM-3 being particularly cited.
Influenced by the results from CARTITUTE-4 + additional results from CARTITUDE-1, CAR-T therapies were also of high interest with cilta-cel the most mentioned molecule.
Dr. Nicolas BLIN, hematologist at Nantes University Hospital, accompanied our experts and had the opportunity to present the poster:
ACTUAL USAGE OF CURRENT SYSTEMIC TREATMENTS AND INFLUENCE OF KEY DRIVERS FOR MULTIPLE MYELOMA IN THE FIRST 2 LINES OF THERAPY. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES
that he co-created with our AplusA experts Melissa YILMAZ and Siegfried ERTL.
You can download and access the poster by clicking the button below:
During the Friday evening poster session, Dr. BLIN presented the results in a detailed video presentation. Access the video by clicking the button below and learn more about our MM data from real-world study:
After the congress, we've held a live webinar with Dr. Nicolas BLIN who highlighted the key moments of the EHA.
Co-moderated by our experts Melissa YILMAZ and Siegfried ERTL, Dr. BLIN presented the latest news on hematology, commented some abstracts based on ongoing clinical trials and shared his thoughts on different hot topics in hematology (Multiple Myeloma, Acute Myeloid Leukemia, Myelofibrosis, bispecific antibodies, CAR T cell therapies, etc.)
Fill this short form to discover the entire newsletter
and to receive next SMML newsletters directly in your mailbox!
👇 👇